A review of two studies demonstrating that large-scale pooled base editor screens can separate pathogenic from benign mutations and identify variants that are associated with altered cellular growth or response to DNA-damaging agents.
25 result(s)
CRISPRaシステムを使用した転写活性化のための化学合成crRNAの有用性を示したThe Journal of Biotechniques掲載（2020年）論文の要約をご紹介します。
Gisela Jimenez-Duranらによる最近の論文は、Horizon Discoveryによって実施された全ゲノムCRISPRノックアウトスクリーニングが、炎症誘発性マクロファージを調節できる既存の阻害剤をどのように同定したかをわかりやすく示しています。
CRISPRノックアウトスクリーニング、CRISPRaスクリーニング、またはCRISPRiスクリーニングの実施をお考えですか？化学合成アレイ化ライブラリーまたはプール化レンチウイルスライブラリーのどちらがプロジェクトに最適かどうかご説明しています。
A summary of a recent publication in The CRISPR Journal showing that Horizon's integrated pooled CRISPRko and high throughput cell panel screening platform together offer clinically relevant information for therapeutic targets.
Here we talk about the role of the Edit-R Pooled sgRNA Indexing PCR Primers and answer the most common questions about the Indexing PCR and Sequencing Primer kit.
Demonstration of a repeatable pooled lentiviral sgRNA screen in primary human T cells
Achieve DNA-free guaranteed gene editing with synthetic predesigned sgRNA reagents and libraries covering the entire human genome.
利用できる多くの選択肢の中から最適なセルベーススクリーニングを選ぶことはたちまちに意思決定が複雑になることがあります。ここでは、主な選択肢である細胞パネルスクリーニングと機能ゲノミクススクリーニングを概観します。
The clinical success rate of new oncology drugs is only 3.4% compared to 20.9% in other disease types (Wong et al, 2018). One contributing factor to this issue is the testing systems used, with two-dimensional (2D) monolayer assay formats as the traditional mainstay of high throughput screening. Although 2D monolayer assays have identified many successful drugs, it is increasingly recognized that they do not accurately model key aspects of the three-dimensional (3D) tumor environment. Therefore, the adoption of high throughput screening approaches using 3D assays to complement 2D approaches could substantially improve prediction of clinical outcomes and reduce the high failure rate of cancer drugs in clinical trials.